🔗 Share this article

Given that America undertakes historic adjustments to its immunization schedules, one figure has surfaced in a surprising turn: Tracy Beth Høeg, an American of Danish descent sports physician and epidemiologist who initially gained attention by expressing skepticism about COVID-19 vaccines during the global health crisis and has focused upon potential deaths following COVID-19 immunization in her brief position at the FDA.

Planned Changes to Pediatric Immunization Schedule

Health officials planned to reveal major changes to the pediatric vaccine schedule in December, aligning the US with Denmark’s vaccine program, according to reports – a significant shift that would put the US out of alignment with a large portion of the world with little proof for benefit. The planned update has been postponed until the next year.

Rather than the director of the vaccine center, Høeg is scheduled to present at the gathering. She was recently named temporary leader of the FDA’s CDER, the fifth person to lead the office this year.

A Shift at the Agency

This interim role could signify a tighter collaboration between the pharmaceutical and vaccine branches as Dr. Høeg and Dr. Prasad strengthen their influence at the FDA – and it signals a increased emphasis upon dismantling long-standing vaccines at the FDA.

The new acting director has repeatedly called for halting certain pediatric immunization guidelines in the US to become more in line with the Danish model, a country with nationalized medicine and a citizenry about the population of the state of Wisconsin.

So far comments, she has continued to focus on vaccination policy – traditionally the purview of Prasad, chief of the FDA’s vaccine center – instead of medication approval.

Concerns Over Qualifications

Dr. Høeg has no obvious background in pharmaceutical research, approval processes or leadership, which has been customary for former heads of the biologics center. She has been employed at the FDA as a senior adviser to the FDA chief and CBER since spring.

“She doesn’t seem to have the requisite experience” for overseeing the drug-regulation department, said Jonathan Howard. “She has not conducted a randomized controlled trial. She is not versed in managing a major agency. She lacks background in industry regulation.”

Previous directors of CBER would “understand laws and regulations and the research of medication creation”, said Janet Woodcock. “Frankly, she has not acquired the sort of resume that former directors who ran the center have had.”

The drug center has an vast range of responsibilities at the agency, she emphasized.

“Everybody just focuses on the innovative therapies, but the off-patent medication office clears numerous off-brand pharmaceuticals. There’s a biosimilars program, over-the-counter program and more, and each of these have to be supervised,” she noted. “The responsibility you overlook, that’s the thing that I always told people is going to cause problems.”

Furthermore, a substantial administrative component to the job, which supervises in excess of 5,000 personnel. “It is a enormous administrative position, if you perform it correctly,” she added.

Agency Reaction and Contentious Programs

Regarding inquiries about Høeg’s qualifications and whether this selection signifies increased cooperation among regulatory chiefs on immunizations, a press secretary stated that the “questions rely on flawed assumptions”.

“Her resume matches the duties of her role,” the representative explained, noting the time Høeg spent counseling the FDA commissioner on “medication safety and oversight research, including computational safety modeling and immunization monitoring”.

As the temporary head, Dr. Høeg takes over the agency head's new fast-track approval initiative, a controversial expedited drug-approval program that apparently worried her preceding directors. “By what process are these drugs being picked for this fast-track system? Who makes the choices?” Dr. Howard said. “There’s a lot of lack of transparency happening at the agency right now.”

In general, he said, “the FDA looks to be trending towards more relaxed rules of all drugs, with the exception of immunizations.”

Public Track Record on Vaccines

Regarding immunizations, Dr. Høeg has a more established, if troubling, history, some experts said. She published a analysis using unverified crowd-sourced reports to determine the incidence of myocarditis after Covid immunization. She consulted for the state of Florida top health official Dr. Joseph Ladapo, who reportedly have modified findings to suggest COVID-19 vaccines are more dangerous than they are.

Included in her “policy goals” for the incoming administration featured revising regulations for new vaccines and discontinuing “unnecessary” immunizations, she remarked post-election on a podcast. At the FDA, Høeg has allegedly proposed preventing adolescent males from getting COVID-19 vaccines.

“She’s an all-around true believer who commences with her beliefs and tailors the evidence to accommodate the data in a highly deceptive, dishonest way,” Dr. Howard argued.

Taking Control and a “Campaign of Retribution”

Høeg aligned with fellow dissenters, {like|